Brazil's health minister and director of the butantan Institute will hold a press conference at 4:00 p.m. local time on the 23rd to announce the results of the three-phase trials of the new coronal vaccine developed by scing in Brazil, according to the information released on the 23rd by the Butantan Research Institute, the partner of the Chinese vaccine enterprise Beijing Kexing company.The Brazilian media "UOL" quoted the statement of Kexing company on the 23rd, saying that the test data of Kexing vaccine in many countries showed that it showed good tolerance in different age groups and could trigger the production of antibodies.
Among the data to be released soon, the most concerned one is the efficiency data of this vaccine. According to the Wall Street Journal on the 22nd, people involved in the trial said the test results showed that the vaccine exceeded the 50% effectiveness threshold that international scientists believe is needed to provide protection. However, "UOL" quoted the butantan Institute as saying that before the launch, any data on vaccine efficiency were only speculation. More than 20000 volunteers participated in the phase III trial in Brazil, Indonesia, Turkey and Chile. The data collected show that the vaccine is safe in different countries, and the results are similar to those seen in China
"UOL" said that after the release of phase III trial data, such as the efficacy rate, the butantan Institute will formally apply to Brazil's national health supervision agency (Anvisa) for registration of the vaccine on the same day, and the latter will evaluate this. If Anvisa's rapid approval can be obtained, the Brazilian state government of Sao Paulo will start vaccination as planned on January 25 next year. According to the butantan Institute, it has received several batches of scing vaccine. In addition, the Institute's kesing vaccine production line has been started. It is estimated that 10.8 million doses of ready-made vaccine will be available for 5.4 million people by the end of 2020. According to the Brazilian news website "G1", Anvisa issued "good practice certification" to Kexing's factories in China on 21 June. The certification is valid for two years, which is a prerequisite for the registration and emergency approval of a vaccine in Brazil. Prior to this, Anvisa sent a team to China to inspect the production process of Kexing vaccine.
Due to the low requirement of storage temperature and competitive price, the vaccine is considered to be the hope of many developing countries such as Brazil. "If this vaccine gets the necessary approval, I will definitely get it," Professor mailer of Brasilia University told the global times on the 23rd. "I think most Brazilians are looking forward to the vaccination, because it can improve the economy, let people return to work, and is the hope for the world to return to normal life." In the past 24 hours, 55202 new cases were confirmed in Brazil, with 7318821 confirmed cases, 968 new deaths and 188259 deaths, according to the epidemic data released by Brazil's Ministry of health on the 22nd. Among them, Sao Paulo state is the most serious. The local government announced on the 22nd that it will tighten the quarantine measures in the state during the Christmas and New Year holidays.
An immunology expert who asked for anonymity told the global times on the 23rd that Kexing vaccine is an inactivated vaccine, and the protection rate may be about 80%. This result is relatively good. The participation of Brazilian and international third-party organizations in the phase III trial and the release of relevant data will also help to enhance the public recognition of the safety and effectiveness of Chinese vaccines and enhance the willingness of overseas vaccination of Chinese vaccines.
Brazil's keshing vaccine data is being watched by many parties. Indonesia's drug regulatory authorities have sought data from Brazil on the safety and efficacy of the vaccine through diplomatic channels, hoping to receive data on the vaccine by December 28, and finally start implementing its vaccination plan in January next year, the Straits Times of Singapore reported on the 23rd. According to reports, Kexing vaccine has also launched a phase III trial in Indonesia. However, due to the small number of volunteers recruited and the lack of vulnerable groups such as medical workers, so far, the data required for approval and registration have not been obtained. Indonesian officials said that the clinical trial of Keshin vaccine in Brazil was earlier and more stringent than that in Indonesia, and the data could be used as the basis for Indonesia's drug administration to evaluate and decide on emergency approval for the use of Kexing vaccine. On December 6, the first batch of 1.2 million doses of Keshin vaccine has arrived in Jakarta, the capital of Indonesia. More vaccines are expected to arrive early next year. Brazil, Indonesia, Singapore and Turkey are expected to use the koshing vaccine in their vaccination programs, the Straits Times said.